Impact of disease progression avoidance by catheter ablation on clinical outcomes in atrial fibrillation: Insights from the CABANA trial
Heart Rhythm · 2026
DOI: 10.1016/j.hrthm.2025.07.050 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Heart Rhythm, 2026. Verfasst von Mingxiao Li und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Engineering Research Center of Medical Devices for Cardiovascular Dise…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Anti-Arrhythmia Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
BACKGROUND: Delaying disease progression by catheter ablation has been recognized in patients with paroxysmal atrial fibrillation (AF); however, its direct association with clinical outcome improvement remains unclear. OBJECTIVE: This study aimed to evaluate the effect of catheter ablation on reducing AF progression and associations with outcomes. METHODS: The Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) trial compared the efficacy of catheter ablation with drug therapy in 2204 patients with AF. CABANA participants with paroxysmal AF at enrollment were included in this subanalysis. The primary endpoint was time to the first documented episode of persistent AF after a 90-day blanking period. RESULTS: Among 2204 CABANA total population, 854 patients had paroxysmal AF at baseline, with 413 patients assigned to catheter ablation and 441 to drug therapy. During a median follow-up of 49.7 months, AF progression occurred in 66 patients (16.0%) of the ablation group compared with 122 patients (27.7%) of the drug treatment group (adjusted hazard ratio 0.52; 95% confidence interval 0.38-0.70). Among participants without AF progression, catheter ablation significantly reduced the incidence of death or cardiovascular hospitalization, whereas no significant effect was observed among those who developed AF progression. The mediation analysis identified that AF progression avoidance explained 23.3% of the treatment effect of catheter ablation compared with drug therapy in reducing death or cardiovascular hospitalization events. CONCLUSION: In this post hoc analysis of the CABANA trial, catheter ablation significantly reduced the occurrence of AF progression. The large randomized trial data provide proof of concept evidence that progression avoidance by ablation may be transformed into clinical outcome improvements.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Engineering Research Center of Medical Devices for Cardiovascular Diseases, Ministry of Education, and National Clinical Research Center for…
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- National Heart, Lung, and Blood Institute
- Beijing Municipal Education Commission
Zitieren
APA
Li, M., Guo, H., Li, E., Jiang, C., Zhao, M., Wang, Z., Wang, J., Shen, T., Xia, S., He, L., Dai, W., Guo, X., Li, S., Liu, N., Jiang, C., Tang, R., Long, D., Sang, C., Du, X., …, & Ma, C. (2026). Impact of disease progression avoidance by catheter ablation on clinical outcomes in atrial fibrillation: Insights from the CABANA trial. Heart Rhythm. https://doi.org/10.1016/j.hrthm.2025.07.050
Vancouver
Li M, Guo H, Li E, Jiang C, Zhao M, Wang Z, et al. Impact of disease progression avoidance by catheter ablation on clinical outcomes in atrial fibrillation: Insights from the CABANA trial. Heart Rhythm. 2026. doi:10.1016/j.hrthm.2025.07.050
BibTeX
@article{Li2026,
author = {Li, Mingxiao and Guo, Hang and Li, Enze and Jiang, Chao and Zhao, Manlin and Wang, Zhen and Wang, Jue and Shen, Ting and Xia, Shijun and He, Liu and Dai, Wenli and Guo, Xueyan and Li, Songnan and Liu, Nian and Jiang, Chenxi and Tang, Ribo and Long, Deyong and Sang, Caihua and Du, Xin and Dong, Jianzeng and Ma, Changsheng},
title = {Impact of disease progression avoidance by catheter ablation on clinical outcomes in atrial fibrillation: Insights from the CABANA trial},
journal = {Heart Rhythm},
year = {2026},
doi = {10.1016/j.hrthm.2025.07.050}
}
EUVIMED